BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 1,949 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 1,949 shares of the business’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $257.24, for a total value of $501,360.76. Following the sale, the chief executive officer owned 5,697,649 shares in the company, valued at approximately $1,465,663,228.76. The trade was a 0.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Oyler also recently made the following trade(s):

• On Monday, June 8th, John Oyler sold 4,940 shares of BeOne Medicines stock. The shares were sold at an average price of $270.56, for a total value of $1,336,566.40.

BeOne Medicines Stock Up 1.4%

Shares of NASDAQ:ONC traded up $3.72 during trading on Monday, reaching $268.20. 351,440 shares of the company traded hands, compared to its average volume of 258,341. BeOne Medicines Ltd. – Sponsored ADR has a 1-year low of $239.25 and a 1-year high of $385.22. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20. The firm has a market cap of $29.43 billion, a P/E ratio of 60.00 and a beta of 0.49. The firm has a fifty day simple moving average of $298.56 and a 200 day simple moving average of $314.03.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. The firm had revenue of $1.51 billion during the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. Analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. EFG International AG acquired a new position in BeOne Medicines during the fourth quarter worth $25,000. Leonteq Securities AG acquired a new position in BeOne Medicines during the fourth quarter worth $35,000. Daiwa Securities Group Inc. acquired a new position in BeOne Medicines during the second quarter worth $35,000. CWM LLC raised its stake in BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after acquiring an additional 39 shares in the last quarter. Finally, Group One Trading LLC acquired a new stake in shares of BeOne Medicines in the fourth quarter valued at $61,000. 48.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Zacks Research raised shares of BeOne Medicines from a “hold” rating to a “strong-buy” rating in a research note on Thursday, June 4th. Morgan Stanley reissued an “overweight” rating and set a $395.00 target price on shares of BeOne Medicines in a research report on Thursday, May 7th. Wolfe Research initiated coverage on BeOne Medicines in a research report on Friday, March 27th. They issued an “outperform” rating and a $340.00 price target for the company. Jefferies Financial Group downgraded BeOne Medicines from a “buy” rating to a “hold” rating and decreased their price target for the stock from $420.00 to $290.00 in a research note on Monday, March 16th. Finally, Royal Bank Of Canada increased their price objective on BeOne Medicines from $425.00 to $436.00 and gave the company an “outperform” rating in a report on Tuesday, June 2nd. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $390.00.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.